Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America

doi:10.1016/j.cardfail.2019.05.007

Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America

,
,

Internal Medicine

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

Original language	English
Pages (from-to)	584-619
Number of pages	36
Journal	Journal of Cardiac Failure
Volume	25
Issue number	8
DOIs	https://doi.org/10.1016/j.cardfail.2019.05.007
State	Published - Aug 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

Funding

Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Shannon M. Dunlay Mayo Clinic, Rochester, MN None None None None None None None Michael M. Givertz Brigham and Women's Hospital None None None None None None None David Aguilar University of Texas Health Science Center None None None None None None None Larry A. Allen University of Colorado School of Medicine AHA † ; NIH, NHLBI † ; PCORI † None None None None ACI Clinical * ; Boston Scientific * ; Cytokinetics/ Amgen * ; Duke Clinical Research Institute * ; Janssen * None Michael Chan University of Alberta, Canada Novartis Company (local hospital PI for a clinical research study) * ; Merck Company (local hospital PI for a clinical research study) * None Novartis * ; Servier * None None Novartis * ; Servier * None Akshay S. Desai Brigham and Women's Hospital Novartis (research grant to Brigham and Women's Hospital) † None None None None Abbott † ; Astra Zeneca † ; Biofourmis * ; Boehringer Ingelheim * ; DalCor Pharma † ; Novartis * ; Regeneron † ; Relypsa * ; Signature Medical * None Anita Deswal Michael E. DeBakey VA Medical Center & Baylor College of Medicine VA Medical Center None None None None None None None Victoria Vaughan Dickson New York University College of Nursing None None None None None None None Mikhail N. Kosiborod Saint Luke's Mid America Heart Institute AstraZeneca (research grant, other research support) † ; Boehringer Ingelheim (research grant) † None None None None Amarin * ; Amgen † ; Applied Therapeutics * ; AstraZeneca † ; Bayer † ; Boehringer Ingelheim † ; Eisai † ; Glytec * ; GlaxoSmithKline * ; Intarcia * ; Janssen † ; Merck (Diabetes) † ; Novartis * ; Novo Nordisk † ; Sanofi † None Carolyn L. Lekavich Duke Clinical Research Institute, Duke University School of Medicine None None None None None None None Rozalina G. McCoy Mayo Clinic Rochester, MN NIH (K23DK114497) * None None None None None None Robert J. Mentz Duke University Medical Center Akros † ; Amgen † ; AstraZeneca † ; Bayer † ; GlaxoSmithKline † ; Luitpold/American Report † ; Medtronic † ; Merck † ; Novartis † (all are research support to institution); NIH (U01HL125511-01A1, U10HL110312, R01AG045551-01A1) † None None None None Abbott * ; Amgen * ; AstraZeneca * ; Bayer * ; BI * ; Merck * ; Novartis † None Ileana L. Piña Montefiore Medical Center None None None None None None None Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Olakunle O. Akinboboye Laurelton Heart Specialists None None None None None None None Charlotte Andersson Herlev Gentofte Hospital (Denmark) None None None None None None None Prakash Deedwania UCSF None None None None None None None Lynne W. Stevenson Vanderbilt University None None None None None None None

Funders	Funder number
Boston Scientific
Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board
Canada Novartis Company
Janssen * None Michael Chan University of Alberta
Servier * None Akshay S. Desai Brigham
VA Medical Center & Baylor College of Medicine VA Medical Center None None None None None None None Victoria Vaughan Dickson New York University College of Nursing None None None None None None None Mikhail N. Kosiborod Saint Luke's Mid America Heart Institute AstraZeneca
Women's Hospital Novartis
National Institutes of Health (NIH)
Merck Company Foundation
AMGen
American Historical Association
Boehringer-Ingelheim	K23DK114497, U01HL125511-01A1, U10HL110312, R01AG045551-01A1
Cytokinetics Incorporated

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

AHA Scientific Statement
Diabetes mellitus, type 2
Drug therapy
Heart failure
Lifestyle
Risk factors

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cardfail.2019.05.007

Cite this

@article{a11bcfd0a8914658b76dfd7ffa75d655,

title = "Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America",

abstract = "Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.",

keywords = "AHA Scientific Statement, Diabetes mellitus, type 2, Drug therapy, Heart failure, Lifestyle, Risk factors",

author = "Dunlay, \{Shannon M.\} and Givertz, \{Michael M.\} and D. Aguilar and Allen, \{Larry A.\} and Michael Chan and Desai, \{Akshay S.\} and A. Deswal and Dickson, \{Victoria Vaughan\} and Kosiborod, \{Mikhail N.\} and Lekavich, \{Carolyn L.\} and McCoy, \{Rozalina G.\} and Mentz, \{Robert J.\} and Pi{\~N}a, \{Ileana L.\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = aug,

doi = "10.1016/j.cardfail.2019.05.007",

language = "English",

volume = "25",

pages = "584--619",

number = "8",

}

TY - JOUR

T1 - Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America

AU - Dunlay, Shannon M.

AU - Givertz, Michael M.

AU - Aguilar, D.

AU - Allen, Larry A.

AU - Chan, Michael

AU - Desai, Akshay S.

AU - Deswal, A.

AU - Dickson, Victoria Vaughan

AU - Kosiborod, Mikhail N.

AU - Lekavich, Carolyn L.

AU - McCoy, Rozalina G.

AU - Mentz, Robert J.

AU - PiÑa, Ileana L.

PY - 2019/8

Y1 - 2019/8

N2 - Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

AB - Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

KW - AHA Scientific Statement

KW - Diabetes mellitus, type 2

KW - Drug therapy

KW - Heart failure

KW - Lifestyle

KW - Risk factors

UR - https://www.scopus.com/pages/publications/85070222492

UR - https://www.scopus.com/pages/publications/85070222492#tab=citedBy

U2 - 10.1016/j.cardfail.2019.05.007

DO - 10.1016/j.cardfail.2019.05.007

M3 - Article

C2 - 31167558

AN - SCOPUS:85070222492

SN - 1071-9164

VL - 25

SP - 584

EP - 619

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

IS - 8

ER -

Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this